CANNABIDIVARIN CBDV: Uses, Side Effects, Interactions and Warnings

CANNABIDIVARIN (CBDV)

Other Names:

2-(3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl)-5-propylbenzene-1,3-diol, Cannabidiverol, CBD-V, CBDV, GWP42006.

Review this Treatment See Brand Products

CANNABIDIVARIN CBDV Overview Information

Cannabidivarin (CBDV) is a chemical in the Cannabis sativa plant. It is similar to cannabidiol (CBD). Like CBD, cannabidivarin does not affect thinking.

Early research suggests that cannabidivarin might make certain nerve cells less active. These nerve cells are involved in swelling (inflammation), seizures, pain, and other conditions. By making these cells less active, cannabidivarin might improve these conditions.

There is interest in using cannabidivarin for seizure disorder, nausea, long-term swelling (inflammation) in the digestive tract, and other conditions, but there is no good scientific evidence to support these uses.

CANNABIDIVARIN CBDV Uses & Effectiveness

Possibly Ineffective for:

Seizure disorder (epilepsy). Taking cannabidivarin for 2 weeks doesn't appear to reduce seizures in people with poorly controlled seizure disorder.

There is interest in using cannabidivarin for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful.

CANNABIDIVARIN CBDV Side Effects & Safety

When taken by mouth: It is possibly safe to take cannabidivarin at a dose of up to 1600 mg daily, for up to 8 weeks. It might cause side effects such as diarrhea, dizziness, headache, sleepiness, and nausea. There isn't enough reliable information to know if cannabidivarin is safe when used in larger doses or for more than 8 weeks.

Special Precautions & Warnings:

Pregnancy and breast-feeding: There isn't enough reliable information to know if cannabidivarin is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.

CANNABIDIVARIN CBDV Interactions

We currently have no information for CANNABIDIVARIN CBDV Interactions

CANNABIDIVARIN CBDV Dosing

There isn't enough reliable information to know what an appropriate dose of cannabidivarin might be. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult a healthcare professional before using.

View clinical references for this vitamin or supplement Sources

References:

Avau B, Borra V, Vanhove AC, Vandekerckhove P, De Paepe P, De Buck E. First aid interventions by laypeople for acute oral poisoning. Cochrane Database Syst Rev. 2018;12(12):CD013230. View abstract.

Brodie MJ, Czapinski P, Pazdera L, et al. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res 2021;6(6):528-536. View abstract.

Deiana S, Watanabe A, Yamasaki Y, et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), ??-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl). 2012;219(3):859-73. View abstract.

Eibach L, Scheffel S, Cardebring M, et al. Cannabidivarin for HIV-Associated Neuropathic Pain: A Randomized, Blinded, Controlled Clinical Trial. Clin Pharmacol Ther. 2020. View abstract.

European Medicines Agency. Public summary of opinion on orphan designation: Cannabidivarin for the treatment of Rett syndrome. Available at: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/17/1921-public-summary-opinion-orphan-designation-cannabidivarin-treatment-rett-syndrome_en.pdf. Accessed December 16, 2019.

European Medicines Agency. Public summary of opinion on orphan designation: Cannabidivarin for treatment of fragile X syndrome. Available at: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/18/1977-public-summary-opinion-orphan-designation-cannabidivarin-treatment-fragile-x-syndrome_en.pdf. Accessed December 16, 2019.

Hill AJ, Mercier MS, Hill TD, et al. Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol. 2012;167(8):1629-42. View abstract.

Hill TD, Cascio MG, Romano B, et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol. 2013;170(3):679-92. View abstract.

Huizenga MN, Sepulveda-Rodriguez A, Forcelli PA. Preclinical safety and efficacy of cannabidivarin for early life seizures. Neuropharmacology. 2019;148:189-198. View abstract.

Iannotti FA, Hill CL, Leo A, et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci. 2014;5(11):1131-41. View abstract.

Iannotti FA, Pagano E, Moriello AS, et al. Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. Br J Pharmacol. 2019;176(10):1568-1584. View abstract.

Pagano E, Romano B, Iannotti FA, et al. The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients. Pharmacol Res. 2019;149:104464. View abstract.

Pretzsch CM, Voinescu B, Lythgoe D, et al. Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy. Transl Psychiatry. 2019;9(1):313. View abstract.

Rock EM, Sticht MA, Duncan M, Stott C, Parker LA. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and ?(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. Br J Pharmacol. 2013;170(3):671-8. View abstract.

Straiker A, Wilson S, Corey W, et al. An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models. Molecules 2021;26(17):5352. View abstract.

US Food and Drug Administration. Orphan Drug Designations and Approvals. Available at: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/. Accessed on March 19, 2021.

Vigli D, Cosentino L, Raggi C, Laviola G, Woolley-Roberts M, De Filippis B. Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome. Neuropharmacology. 2018;140:121-129. View abstract.

Zagzoog A, Mohamed KA, Kim HJJ, et al. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci Rep 2020;10(1):20405. View abstract.

Zamberletti E, Gabaglio M, Piscitelli F, et al. Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice. J Psychopharmacol. 2019;33(7):894-907. View abstract.

Zamberletti E, Gabaglio M, Woolley-Roberts M, Bingham S, Rubino T, Parolaro D. Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats. Front Cell Neurosci. 2019;13:367. View abstract.

Be the first to share your experience with this treatment.

Learn about User Reviews and read IMPORTANT information about user generated content

Conditions of Use and Important Information: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version. © Therapeutic Research Faculty 2009.

Today on WebMD